Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)
Anti-HIV Immune Serum Globulin (Human)
Blood-Borne Infections+14
+ Urogenital Diseases
+ Genital Diseases
Treatment Study
Summary
To investigate the potential benefit of providing passive immunity with hyperimmune anti-HIV human serum.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.12 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria Patients must have: Proof of HIV infection. Diagnosis of asymptomatic HIV infection or early AIDS related complex (ARC) with no zidovudine (AZT) or other anti-HIV therapy. OR a diagnosis of AIDS and = or > 3 months of AZT therapy. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: HIV-induced neurological disease. IgA negative. Concurrent Medication: Excluded: Immunomodulating agents. Steroids. Interferons. Patients with the following are excluded: Active substance abuse. Use of immunomodulating drugs such as steroids or interferons. HIV-induced neurological disease. IgA negative. Required with a diagnosis of AIDS: = or > 3 months of zidovudine (AZT) therapy. Active substance abuse.
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location